A randomized phase 3 double-blinded study comparing the efficacy and safety of niraparib to placebo in participants with either triple-negative breast cancer or her2-negative BRCA-mutated breast cancer with molecular disease based on presence of circulating tumor DNA after definitive therapy.

Principal investigator: Tytti Ahola
Trial site: HUS Comprehensive Cancer Center

Link to the ClinicalTrials.gov website